Inflammaging and osteoarthritis - therapeutic opportunities

Area of Science:

• Biomedical Science
• Molecular Biology
• Rheumatology

Background:

• Cellular senescence, characterized by the senescence-associated secretory phenotype (SASP), contributes to chronic inflammation and tissue degradation.
• In osteoarthritis (OA), SASP secreted by chondrocytes and macrophages exacerbates inflammation and extracellular matrix (ECM) breakdown.
• Key signaling pathways including NF-κB, MAPK/p38, mTOR, AMPK, and JAK/STAT are activated by senescent cells, sustaining OA pathogenesis.

Purpose of the Study:

• To review the molecular mechanisms linking SASP to OA pathogenesis.
• To highlight novel therapeutic strategies targeting SASP-related pathways for OA treatment.

Main Methods:

• Literature review of recent studies on cellular senescence, SASP, and OA.
• Analysis of molecular mechanisms involving key signaling pathways in OA.
• Evaluation of pharmacological and gene-based therapeutic approaches.

Main Results:

• SASP drives OA through pro-inflammatory cytokines, chemokines, and proteases.
• Senescent chondrocytes and macrophages activate critical signaling pathways contributing to ECM degradation.
• Pharmacological agents (e.g., anakinra, metformin, rapamycin) and gene-based methods (e.g., microRNA, CRISPR/Cas9) show promise in modulating SASP.

Conclusions:

• SASP is a key driver of osteoarthritis.
• Targeting SASP pathways offers a promising therapeutic avenue for OA.
• Novel strategies aim to attenuate inflammation, preserve cartilage, and slow OA progression.